Acyl-Alkyl-Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer's Disease as Identified by Targeted Metabolomics

Diagnosis of Alzheimer's disease (AD) is still a challenge. Salivary analysis could produce an easily accessible and inexpensive possibility to study metabolic changes in AD. In the present pilot study, we show for the first time using targeted metabolomics that acyl-alkyl phosphatidylcholines (PCae C34:1-2; PCae C36:1-2-3; PCaeC38:1-3; PCae C40:2-3) are significantly reduced in saliva of AD patients (n = 25) compared to healthy controls (n = 25). Saliva levels of PCae C36:(1-2-3) were also decreased in patients with mild cognitive impairment (n = 25). No changes were seen for saliva diacyl-phosphatidylcholines, lyso-acyl-phosphatidylcholines, and sphinogomyelins. These data suggest specific lipid changes in the saliva of AD patients, thus salivary measures could establish new biomarkers. However, these preliminary results have to be established in larger scale studies.